An Overview of ADAM9: Structure, Activation, and Regulation in Human Diseases

被引:62
作者
Chou, Cheng-Wei [1 ,2 ]
Huang, Yu-Kai [1 ]
Kuo, Ting-Ting [3 ]
Liu, Jing-Pei [1 ]
Sher, Yuh-Pyng [1 ,3 ,4 ]
机构
[1] China Med Univ, Grad Inst Biomed Sci, Taichung 404, Taiwan
[2] Taichung Vet Gen Hosp, Div Hematol Med Oncol, Dept Med, Taichung 407, Taiwan
[3] China Med Univ Hosp, Ctr Mol Med, Taichung 404, Taiwan
[4] China Med Univ, Chinese Med Res Ctr, Taichung 404, Taiwan
关键词
ADAM9; biological function; inflammation; cancer; HEPATOCELLULAR-CARCINOMA; PANCREATIC-CANCER; LUNG-CANCER; CELL-PROLIFERATION; TARGETING ADAM9; METALLOPROTEASE-DISINTEGRIN; CRYSTAL-STRUCTURES; ENDOTHELIAL-CELL; TUMOR-CELLS; EXPRESSION;
D O I
10.3390/ijms21207790
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
ADAM9 (A disintegrin and a metalloprotease 9) is a membrane-anchored protein that participates in a variety of physiological functions, primarily through the disintegrin domain for adhesion and the metalloprotease domain for ectodomain shedding of a wide variety of cell surface proteins. ADAM9 influences the developmental process, inflammation, and degenerative diseases. Recently, increasing evidence has shown that ADAM9 plays an important role in tumor biology. Overexpression of ADAM9 has been found in several cancer types and is correlated with tumor aggressiveness and poor prognosis. In addition, through either proteolytic or non-proteolytic pathways, ADAM9 promotes tumor progression, therapeutic resistance, and metastasis of cancers. Therefore, comprehensively understanding the mechanism of ADAM9 is crucial for the development of therapeutic anti-cancer strategies. In this review, we summarize the current understanding of ADAM9 in biological function, pathophysiological diseases, and various cancers. Recent advances in therapeutic strategies using ADAM9-related pathways are presented as well.
引用
收藏
页码:1 / 22
页数:22
相关论文
共 50 条
  • [41] ADAM9 is present at endothelial cell - cell junctions and regulates monocyte - endothelial transmigration
    English, William R.
    Siviter, Richard J.
    Hansen, Martin
    Murphy, Gillian
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2017, 493 (02) : 1057 - 1062
  • [42] ADAM9 Inhibition Increases Membrane Activity of ADAM10 and Controls α-Secretase Processing of Amyloid Precursor Protein
    Moss, Marcia L.
    Powell, Gary
    Miller, Miles A.
    Edwards, Lori
    Qi, Bin
    Sang, Qing-Xiang Amy
    De Strooper, Bart
    Tesseur, Ina
    Lichtenthaler, Stefan F.
    Taverna, Mara
    Zhong, Julia Li
    Dingwall, Colin
    Ferdous, Taheera
    Schlomann, Uwe
    Zhou, Pei
    Griffith, Linda G.
    Lauffenburger, Douglas A.
    Petrovich, Robert
    Bartsch, Joerg W.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2011, 286 (47) : 40443 - 40451
  • [43] MiR-126 inhibits cell migration and invasion by targeting ADAM9 in oral squamous cell carcinoma
    Qin, W-J
    Lv, L-H
    Zhang, M.
    Zhou, X.
    Liu, G-Q
    Lu, H-J
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2019, 23 (23) : 10324 - 10331
  • [44] miR-126 regulated breast cancer cell invasion by targeting ADAM9
    Wang, Cheng-Zheng
    Yuan, Peng
    Li, Yin
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2015, 8 (06): : 6547 - 6553
  • [45] A Disintegrin and Metalloproteinase 9 Domain (ADAM9) Is a Major Susceptibility Factor in the Early Stages of Encephalomyocarditis Virus Infection
    Bazzone, Lindsey E.
    King, Michael
    MacKay, Christopher R.
    Kyawe, Pyae P.
    Meraner, Paul
    Lindstrom, Daniel
    Rojas-Quintero, Joselyn
    Owen, Caroline A.
    Wang, Jennifer P.
    Brass, Abraham L.
    Kurt-Jones, Evelyn A.
    Finberg, Robert W.
    MBIO, 2019, 10 (01):
  • [46] MiR-129-5p functions as a tumor suppressor in gastric cancer progression through targeting ADAM9
    Liu, Qi
    Jiang, Jianwu
    Fu, Yang
    Liu, Tao
    Yu, Yang
    Zhang, Xiefu
    BIOMEDICINE & PHARMACOTHERAPY, 2018, 105 : 420 - 427
  • [47] Expression of ADAM9 in CIN3 lesions and squamous cell carcinomas of the cervix
    Zubel, Angela
    Flechtenmacher, Christa
    Edler, Lutz
    Alonso, Angel
    GYNECOLOGIC ONCOLOGY, 2009, 114 (02) : 332 - 336
  • [48] ADAM9 is over-expressed in human ovarian clear cell carcinomas and suppresses cisplatin-induced cell death
    Ueno, Mari
    Shiomi, Takayuki
    Mochizuki, Satsuki
    Chijiiwa, Miyuki
    Shimoda, Masayuki
    Kanai, Yae
    Kataoka, Fumio
    Hirasawa, Akira
    Susumu, Nobuyuki
    Aoki, Daisuke
    Okada, Yasunori
    CANCER SCIENCE, 2018, 109 (02) : 471 - 482
  • [49] ADAM9 Mediates Triple-Negative Breast Cancer Progression via AKT/NF-κB Pathway
    Zhou, Rui
    Cho, William C. S.
    Ma, Victor
    Cheuk, Wah
    So, Yik-Ka
    Wong, S. C. Cesar
    Zhang, Mingrong
    Li, Cong
    Sun, Yujie
    Zhang, Hong
    Chan, Lawrence W. C.
    Tian, Mei
    FRONTIERS IN MEDICINE, 2020, 7
  • [50] ADAM9 Is a Novel Product of Polymorphonuclear Neutrophils: Regulation of Expression and Contributions to Extracellular Matrix Protein Degradation during Acute Lung Injury
    Roychaudhuri, Robin
    Hergrueter, Anja H.
    Polverino, Francesca
    Laucho-Contreras, Maria E.
    Gupta, Kushagra
    Borregaard, Niels
    Owen, Caroline A.
    JOURNAL OF IMMUNOLOGY, 2014, 193 (05) : 2469 - 2482